Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study

Publication date: Available online 28 January 2021Source: The Lancet Respiratory MedicineAuthor(s): Mark A Chilvers, Jane C Davies, Carlos Milla, Simon Tian, Zifei Han, Alexandra G Cornell, Caroline A Owen, Felix Ratjen
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research